A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969

Phase 1 Recruiting 100 enrolled InSilico Medicine

RandomizedSequentialDouble-blindTreatment

Summary

This is a single center, phase 1, randomized, double-blind, placebo-controlled sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of ISM8969 in healthy adults and elderly participants and obese adult participants at risk of cardiovascular disease.

Timeline

Start: 2026-06-15
Primary completion: 2027-01-29
Completion: 2027-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ISM8969	Unknown	—	Oral

Indications

No indication recorded.